Joslin Diabetes Center is planning to assess CME (Certified Continuing Medical Education) in an effort to create accurate diabetes care methodologies. The research is fully funded, with Pfizer Corp. covering half of the support and issuing a “challenge” for other companies to join in – a call taken up by GlaxoSmithKline and Eli Lilly & Co., who also are funding the work.
The center noted in a news release that the findings from the research initiative are expected to help establish clinical performance standards in medical education, including methods for self-reporting, chart-pulling and assessing competency in the areas of diabetes and cardiometabolic risk.
“Joslin’s publication of results from this research initiative will provide valuable information on the effectiveness of medical education that utilizes an evidence-based design to improve clinical performance and patient health outcomes,” according to a statement by William Sigmund, senior vice president of North America Medical Affairs at GlaxoSmithKline.
The research, which incorporates data tracked electronically in clinical practice, is ready to begin gathering data in the second and third quarters of 2012, the release said.
Joslin Diabetes Center is a teaching and research-affiliated hospital of Harvard Medical School.